

Supplementary Materials

Supplementary Table 1. Non-participants and Participants Demographic and Treatment Characteristics

	Non-Participants N=178		Participants N=265		P-value
Demographics	N	%	N	%	
Gender					
Female	82	46.1	137	51.7	0.24
Male	96	53.9	128	48.3	
Race					
White	162	91.0	241	90.9	0.98
Other	16	9.0	24	9.06	
	Mean	SD	Mean	SD	
Current Age (yrs)	37.8	6.4	37.1	6.6	0.27
Treatment Characteristics	Mean	SD	Mean	SD	
IT MTX (mg/m ²)	142.5	108.6	143.0	113.3	0.96
IV MTX (g/m ²)	2286.2	2450.8	2860.3	3453.2	0.04*
Age at CRT (yrs)	6.4	3.8	6.9	4.0	0.27
Time from CRT (yrs)	27.4	6.2	30.3	6.5	<.001
RT Dose	N	%	N	%	
24 Gy	106	59.6	138	52.1	0.12
18 Gy	72	40.5	127	47.9	

* Participants had greater exposure to Methotrexate (MTX) than did non-participants. However, MTX, even at this higher dose, was not statistically significantly associated with Memory Impairment in this study (Table 4). Additional information on those who refused the study was not uniformly available.

Supplementary Table 2: Immediate and Delayed Memory Impairment Rates by Age at Evaluation and CRT Dose

Current Age, y	<u>Immediate Memory, % Impaired</u>		<u>Delayed Memory, % Impaired</u>	
	18 Gy	24 Gy	18 Gy	24 Gy
<30	14	40	16	40
30-40	19	40	14	32
>40	17	28	17	27

Current Age, y	<u>Immediate Memory, % Impaired (95% Exact CI)</u>		<u>Delayed Memory, % Impaired (95% Exact CI)</u>	
	18 Gy	24 Gy	18 Gy	24 Gy
<30	13.5 (4.5-28.8)	40.0 (5.3-85.3)	16.2 (6.1-32.0)	40 (5.3-85.3)
30-40	19.5 (11.3-30.1)	40.0 (27.0-54.1)	14.3 (7.4-24.1)	32.7 (20.7-46.7)
>40	16.7 (2.1-48.4)	29.0 (19.1-40.5)	16.7 (2.1-48.4)	27.6 (18.0-39.1)

Supplementary Figure 1. Study Recruitment Flow Diagram

